docetaxel anhydrous has been researched along with nintedanib in 36 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (nintedanib) | Trials (nintedanib) | Recent Studies (post-2010) (nintedanib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 846 | 133 | 801 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 27 (75.00) | 24.3611 |
| 2020's | 9 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Alexandre, J; Bousquet, G; de Mont-Serrat, H; Faivre, S; Goldwasser, F; Kaiser, R; Le Tourneau, C; Misset, JL; Raymond, E | 1 |
| Barrueco, J; Bondarenko, I; Douillard, JY; Gann, CN; Gaschler-Markefski, B; Gottfried, M; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; von Pawel, J | 1 |
| Yaqub, F | 1 |
| Chevreau, C; De Mont-Serrat, H; Droz, JP; Kaiser, R; Medioni, J; Merger, M; Oudard, S; Stopfer, P | 1 |
| Heigener, D; Reck, M; Reinmuth, N | 2 |
| Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N | 1 |
| Fahrbach, K; Griebsch, I; Kaiser, R; Martin, A; Mellemgaard, A; Popat, S; Reck, M; Rizzo, M | 1 |
| Barrueco, J; Bondarenko, I; Douillard, JY; Gaschler-Markefski, B; Gottfried, M; Griebsch, I; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Palmer, M; Reck, M; von Pawel, J | 1 |
| Dhillon, S | 1 |
| Georgoulias, V; Nintos, G; Syrios, J | 1 |
| Bronte, G; Galvano, A; Passiglia, F; Russo, A | 1 |
| Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K | 1 |
| Asensi Diez, R; Clopes Estela, A; Espinosa Bosch, M; García Agudo, S | 1 |
| Gann, CN; Kaiser, R; Morsli, N | 1 |
| Abate, MI; Cortinovis, D; Gregorc, V; Malapelle, U; Manzo, A; Migliorino, MR; Morabito, A | 1 |
| Griebsch, I; Hastedt, C; Mellemgaard, A; Popat, S; Reck, M | 1 |
| Bennouna, J; Bondarenko, I; Douillard, JY; Gottfried, M; Heigener, DF; Kaiser, R; Krzakowski, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; Stöhr, J; Summers, Y; von Pawel, J | 1 |
| Alcaraz, J; Gabasa, M; Hilberg, F; Ikemori, R; Reguart, N | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J | 1 |
| Goto, K; Horinouchi, H; Kato, T; Kenmotsu, H; Morsli, N; Nakagawa, K; Saito, I; Sarashina, A; Takeda, K; Takeda, M; Tanaka, T; Yamamoto, N | 1 |
| An, HJ; Chae, YS; Hong, SH; Jang, TW; Kang, JH; Kim, K; Lee, SS; Lee, YG; Park, IC; Yuh, YJ | 1 |
| Barrueco, J; Grohé, C; Hilberg, F; Huber, RM; Kaiser, R; Kerr, KM; Manegold, C; Park, K; Pavlakis, N; Paz-Ares, L; Popat, S; Reck, M; Thatcher, N | 1 |
| Carcereny, E; Corral, J; Cortes, ÁA; Domine, M; García, Y; Llorente, M; López Criado, MP; López Picazo, JM; Majem, M; Rodríguez-Abreu, D | 1 |
| de Castro, J; Felip, E; García-Campelo, R; Garrido, P; Isla, D; Lianes, P; Paz-Ares, L; Trigo, JM | 1 |
| Acevedo-Delgado, JA; Acosta-Espinoza, A; Alatorre-Alexander, JA; Astorga-Ramos, AM; Barriguete-Parra, L; Campos-Gomez, S; Capdeville-García, D; Cázarez-Price, JC; Ceja-García, JP; Fernández-Garibay, VM; Flores-Anaya, N; Flores-Mariñelarena, RR; García-Montes, V; Gerson-Cwilich, R; González-Espinoza, IR; Gonzalez-Villanueva, JI; Kuri-Exsome, R; Magallanes-Maciel, M; Martínez-Barrera, L; Noriega-Iriondo, MF; Perales-Rodríguez, E; Perez-Lozano, Y; Rodríguez-Cid, JR; Rodríguez-Silva, C; Suárez-García, D; Vázquez-Cortés, L; Villalobos-Prieto, A; Zuloaga-Fernandez, CJ | 1 |
| Blakely, CM; McCoach, CE | 1 |
| Buchner, H; Fischer, JR; Kaiser, R; Kerr, K; Kitzing, T; Miliauskas, S; Radonjic, D; Reck, M; Syrigos, K; Zöchbauer-Müller, S | 1 |
| Atz, J; Azeh, I; Buchner, H; C Christoph, D; Hoffmann, C; Hoiczyk, M; Kambartel, K; Metzenmacher, M; Panse, J; Rizzo, F; Schaufler, D; Scheffler, M; Turki, AT | 1 |
| Auliac, JB; Bizieux, A; Chouaid, C; Falchero, L; Geier, M; Greillier, L; Guisier, F; Lamy, R; Le Garff, G; Monnet, I; Ricordel, C; Vergnenegre, A | 1 |
| Atz, J; Blau, W; Gleiber, W; Grohé, C; Haas, S; Hammerschmidt, S; Kaiser, R; Krüger, S; Müller-Huesmann, H; Schulze, M; Wehler, T | 1 |
| Badovinac, S; Bitar, L; Jakopovic, M; Janzic, U; Korsic, M; Kukulj, S; Ljubicic, L; Mohorcic, K; Plestina, S; Samarzija, M; Seiwerth, F; Terglav, AS; Unk, M | 1 |
| Lorence, RM; Radonjic, D; Reck, M; Schuette, W; Urban, T; von Wangenheim, U; Westeel, V | 1 |
10 review(s) available for docetaxel anhydrous and nintedanib
| Article | Year |
|---|---|
Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Survival Rate; Taxoids | 2014 |
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Taxoids; Treatment Outcome | 2015 |
Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Indoles; Lung Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Ramucirumab; Taxoids; Vascular Endothelial Growth Factor A | 2015 |
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Survival Rate; Taxoids | 2015 |
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Italy; Lung Neoplasms; Nivolumab; Ramucirumab; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Indoles; Network Meta-Analysis; Nivolumab; Ramucirumab; Taxoids; Treatment Outcome | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Docetaxel; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Immunotherapy; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Quality of Life; Taxoids; Thymine; Trifluridine; Uracil | 2018 |
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung; Lung Neoplasms; Patient Selection; Ramucirumab; Time Factors | 2019 |
10 trial(s) available for docetaxel anhydrous and nintedanib
| Article | Year |
|---|---|
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Topics: Administration, Oral; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2011 |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2014 |
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tubulin Modulators | 2014 |
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Taxoids | 2015 |
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Double-Blind Method; Health Status; Humans; Indoles; Lung Neoplasms; Placebos; Quality of Life; Self Report; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2015 |
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Taxoids; Treatment Outcome | 2016 |
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Europe; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2017 |
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Feasibility Studies; Female; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; No-Observed-Adverse-Effect Level; Treatment Outcome | 2018 |
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Taxoids; Treatment Outcome | 2021 |
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Treatment Outcome | 2023 |
16 other study(ies) available for docetaxel anhydrous and nintedanib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
[Therapeutic option after failure of first-line chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Evidence-Based Medicine; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2015 |
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Ramucirumab; Taxoids; Therapies, Investigational | 2016 |
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Taxoids; Treatment Outcome | 2015 |
Industry corner: perspectives and controversies - The challenges of patient access to new medicines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Industry; Drugs, Investigational; European Union; Health Services Accessibility; Humans; Indoles; Lung Neoplasms; Needs Assessment; Taxoids | 2017 |
Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Docetaxel; Fibroblasts; Fibrosis; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transforming Growth Factor beta1 | 2017 |
Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Retreatment; Treatment Outcome | 2019 |
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Indoles; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Decision-Making; Consensus; Delphi Technique; Disease Progression; Docetaxel; Humans; Immunotherapy; Indoles; Lung Neoplasms; Mutation; Spain | 2020 |
Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Indoles; Lung; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2020 |
Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Indoles; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Indoles; Lung Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2020 |
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Treatment Failure | 2021 |
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2022 |
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung; Lung Neoplasms; Retrospective Studies | 2023 |